Learn more about the BAGUERA® C Cervical Disc Replacement Clinical Trial

Institute of Neuro Innovation is now enrolling patients in two clinical trials evaluating a new cervical disc replacement option for patients with degenerative cervical disc disease. 

The clinical trials are evaluating the BAGUERA® C cervical artificial disc, which is designed to help maintain the natural behavior and mobility of a functional cervical spine. While the BAGUERA C is new in the U.S and only available in these clinical trials, more than 35,000 have been implanted in patients in more than 40 countries outside the U.S. since 2007.

Approximately 5% of people under age 50 have disc degeneration, while 90% of people over age 50 have some level of degenerative disc disease.i By age 60, most people will have some level of disc degeneration.ii

Unlike spinal disc fusion, a common surgical treatment option, the goal of cervical disc replacement is to help preserve motion of the cervical spine or spinal segment after surgery. This can provide patients with improved quality of life after treatment.

Patients who are candidates for the clinical trials include people who suffer from symptomatic cervical disc disease affecting one level or two adjacent levels between C3 and C7, and who experience the following signs and symptoms:

• Neck or arm pain, and/or

• Functional and/or neurological deficit accompanied by at least one of the following conditions confirmed by MRI or X-Ray:

  • Herniated nucleus pulposus; and/ or

  • Spondylarthrosis defined by the presence of osteophytes; and/ or

  • Reduction of disc height 

• No response to non-surgical treatment for a period of at least six weeks, or symptoms or signs of progressive root compression despite conservative treatment.

• Age between 22 to 69

For more information on the clinical trial or eligibility, please contact the INI’s study coordinator at research@inifoundation.org.